Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Research & Development (2017 - 2025)

VYNE Therapeutics' Research & Development history spans 9 years, with the latest figure at $4.9 million for Q2 2025.

  • For Q2 2025, Research & Development fell 33.19% year-over-year to $4.9 million; the TTM value through Jun 2025 reached $30.9 million, up 78.26%, while the annual FY2025 figure was $19.2 million, 37.84% down from the prior year.
  • Research & Development reached $4.9 million in Q2 2025 per VYNE's latest filing, down from $6.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $10.2 million in Q3 2024 to a low of $2.7 million in Q1 2023.
  • Average Research & Development over 5 years is $5.3 million, with a median of $4.7 million recorded in 2022.
  • Peak YoY movement for Research & Development: crashed 73.33% in 2021, then soared 220.34% in 2024.
  • A 5-year view of Research & Development shows it stood at $4.3 million in 2021, then dropped by 1.04% to $4.3 million in 2022, then decreased by 29.35% to $3.0 million in 2023, then skyrocketed by 220.34% to $9.7 million in 2024, then crashed by 49.6% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Research & Development are $4.9 million (Q2 2025), $6.1 million (Q1 2025), and $9.7 million (Q4 2024).